Director of Invivyd, Inc. Sells Shares Worth Over $30,000

On December 16th, 2023, Terrance Mcguire, a director at Invivyd, Inc. (NASDAQ:IVVD), sold 65,359 shares of the company’s stock. The shares were sold at an average price of $0.47, resulting in a total transaction value of $30,718.73. Following this transaction, Mcguire retains direct ownership of 4,012,320 shares, which are currently valued at approximately $1,885,790.40. This sale represents a 1.60% reduction in his total holdings.

The sale is documented in a filing with the Securities and Exchange Commission (SEC) and can be accessed through their official website.

Recently, Mcguire has made a few significant trades, including:

• On December 11th, he sold 160,400 shares for a total of $94,636.00, at an average price of $0.59.
• On December 9th, he sold 150,000 shares for $91,500.00, at an average price of $0.61.

Stock Performance Overview

On the day of Mcguire’s latest sale, Invivyd's stock traded down by 17.6%, falling to $0.45. The trading volume for the day was 1,228,420 shares, significantly higher than the average volume of 651,886 shares. The company has a fifty-day moving average stock price of $0.82 and a 200-day moving average of $1.05. With a market capitalization of $53.89 million, the stock has a P/E ratio of -0.23 and a beta of 0.53, indicating a low level of volatility. Over the past year, the stock reached a low of $0.45 and a high of $5.20.

Analysts and Price Targets

Several financial analysts have revised their target prices for Invivyd’s stock. A report from Morgan Stanley recently reduced their target price from $9.50 to $3.55, maintaining an "overweight" rating on the stock. HC Wainwright also lowered their target from $15.00 to $10.00, while maintaining a "buy" rating. In contrast, EF Hutton Acquisition Co. I upgraded Invivyd to a "strong-buy" rating. Additionally, D. Boral Capital reaffirmed a "buy" rating with a target price set at $9.00. Currently, MarketBeat reports four analysts have issued buy recommendations, while one has assigned a strong buy rating, giving the stock a consensus rating of "Buy" with an average target price of $7.89.

Institutional Ownership Trends

A number of institutional investors have recently adjusted their stakes in Invivyd. State Street Corp increased its ownership by 3.7% in the third quarter, now holding 1,018,640 shares valued at approximately $1,039,000. Marshall Wace LLP raised its position by 4.2% in the second quarter, holding 786,899 shares worth around $866,000. Acadian Asset Management LLC significantly increased its stake by 232.0% and currently owns 678,706 shares worth $745,000. Additionally, Duquesne Family Office LLC purchased shares worth $629,000 in the second quarter, while Renaissance Technologies LLC invested $421,000 in the same period. Institutional and hedge fund ownership accounts for 70.36% of the company's stock.

About Invivyd, Inc.

Invivyd, Inc. is a commercial-stage biopharmaceutical company that specializes in the discovery, development, and commercialization of antibody-based solutions targeting infectious diseases in the United States. Their notable product is INVYMAB, which integrates viral surveillance and predictive modeling along with advanced antibody engineering.

Conclusion

In light of recent activity by company insiders and fluctuations in stock performance, potential investors and market watchers will want to stay informed about Invivyd’s developments as well as analysts’ insights regarding stock performance.

Invivyd, Stocks, Director